Semaglutide EVOKE Alzheimer’s Trial — PatSnap Eureka
Semaglutide EVOKE Trial: GLP-1 Receptor Agonism in Alzheimer's Disease
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials are testing oral semaglutide (14 mg daily) in ~3,700 participants with early symptomatic Alzheimer's disease — a landmark test of whether GLP-1 biology extends beyond obesity into neurodegeneration.
Why GLP-1 Receptor Agonism May Modify Alzheimer's Disease
The National Institutes of Health-supported concept that Alzheimer's disease represents a form of brain insulin resistance — sometimes called "type 3 diabetes" — provides the central mechanistic rationale for the EVOKE program. Impaired insulin signaling in the brain leads to tau hyperphosphorylation, reduced BDNF expression, increased amyloid-β production, and synaptic dysfunction. GLP-1 receptor agonists, by restoring insulin-like signaling in neurons, may reverse several of these pathological cascades.
The PatSnap life sciences intelligence platform has indexed multiple Novo Nordisk patents (including EP3936138A1 and US20230149532A1) disclosing methods for treating AD using semaglutide, with claimed biomarkers of response including plasma NfL, CSF amyloid-β42/40 ratio, and tau-PET imaging endpoints. GLP-1 receptor immunoreactivity has been confirmed in hippocampal neurons, astrocytes, and microglia — providing a direct cellular basis for CNS action.
Preclinical studies consistently demonstrate that GLP-1RAs, including liraglutide and semaglutide, reduce amyloid-β plaques, tau hyperphosphorylation, neuroinflammation, and oxidative stress in animal models of AD. Semaglutide exhibited superior effects compared with liraglutide at equivalent doses, potentially related to its longer half-life and greater CNS penetration. In APP/PS1 transgenic mice, 12 weeks of subcutaneous semaglutide treatment significantly reduced hippocampal amyloid plaque burden, improved dendritic spine density, and restored long-term potentiation.
The World Health Organization estimates over 55 million people live with dementia globally — underscoring the enormous unmet need that a disease-modifying GLP-1RA therapy could address. Learn more about the patent landscape analytics driving this research frontier.
Semaglutide in Neurodegeneration: Key Data Visualised
Patent and literature analysis from PatSnap Eureka surfaces the quantitative signals underpinning the EVOKE program's scientific and commercial rationale.
Phase 2 Adverse Event Profile — Oral Semaglutide in Elderly AD Patients
GI adverse events were the primary tolerability signal in the 120-patient Phase 2 dose-ranging study (3–14 mg), informing EVOKE dose selection.
EVOKE Trial Endpoint Architecture: Clinical vs. Biomarker Measures
The EVOKE program uses a dual-track endpoint strategy — clinical-functional outcomes as primary measures, and imaging/fluid biomarkers as pharmacodynamic readouts of disease modification.
How Semaglutide Acts in the Alzheimer's Disease Brain
Preclinical and mechanistic evidence from patent literature and peer-reviewed research identifies multiple convergent neuroprotective mechanisms activated by GLP-1 receptor agonism.
Reduction of Amyloid-β Plaque Burden
Semaglutide treatment significantly reduced amyloid-β plaque burden in 5xFAD and APP/PS1 mouse models of Alzheimer's disease. In APP/PS1 mice, 12 weeks of subcutaneous semaglutide significantly reduced hippocampal amyloid plaque burden and restored long-term potentiation. Novo Nordisk's EP3936138A1 patent claims methods targeting GLP-1 receptor activation in CNS neurons to reduce amyloid-β deposition.
Confirmed in 5xFAD & APP/PS1 modelsSuppression of Tau Hyperphosphorylation
GLP-1 receptor signaling suppresses tau kinase activity, particularly GSK-3β and CDK5, thereby reducing tau phosphorylation and tangle formation. In human iPSC-derived neurons harboring MAPT mutations, semaglutide treatment reduced AT8-positive tau burden and increased microtubule stability. Both GLP-1 receptor agonists significantly reduced tau phosphorylation in streptozotocin-induced rat models of sporadic Alzheimer's disease.
GSK-3β & CDK5 kinase suppressionMicroglial Polarisation & Inflammasome Inhibition
Semaglutide reduced IL-1β and TNF-α release from LPS-stimulated microglia, shifted microglial polarization toward an anti-inflammatory phenotype, and decreased NLRP3 inflammasome activation. GLP-1 analogues modulate microglial phenotype from pro-inflammatory M1 to anti-inflammatory M2 states. In astrocytes, semaglutide normalized reactive astrogliosis markers. The PatSnap life sciences platform tracks over 200 patent families in this space.
NLRP3 inflammasome suppressedBDNF Upregulation & Synaptic Restoration
GLP-1 receptor activation promotes neurogenesis, synaptic plasticity, and cognitive function. Both liraglutide and semaglutide significantly improved BDNF signaling, reduced microglial activation, and improved spatial memory in streptozotocin models. In APP/PS1 mice, semaglutide improved dendritic spine density and restored long-term potentiation. Single-nucleus RNA sequencing revealed transcriptional shifts in oligodendrocyte precursors and excitatory neurons consistent with improved synaptic and axonal function.
BDNF & LTP restoration confirmedEVOKE Trial Biomarker & Endpoint Reference Table
A comprehensive mapping of clinical, functional, and pharmacodynamic endpoints used across the EVOKE and EVOKE+ Phase 3 program.
Novo Nordisk's IP Strategy in GLP-1 Neurodegeneration
PatSnap Eureka analysis of Novo Nordisk's patent portfolio reveals a multi-layered IP strategy spanning mechanism, formulation, combination therapy, and biomarker-defined patient selection.
Core Mechanism Patents
US20210346454A1 (Novo Nordisk) covers use of GLP-1 receptor agonists including semaglutide for treating Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Claims include reducing amyloid-β aggregation, tau hyperphosphorylation, synaptic loss, and neuroinflammation through GLP-1 receptor activation with BDNF upregulation and NF-κB inhibition.
Oral Formulation & CNS Delivery
US20230149532A1 claims methods for treating MCI or mild dementia due to AD using oral semaglutide with the SNAC absorption enhancer system to achieve therapeutically relevant CNS exposure. The 14 mg oral dose used in EVOKE was selected to maximize CNS exposure while maintaining manageable GI tolerability, as validated in the Phase 2 dose-ranging study in 120 elderly patients.
Oral Semaglutide and Blood-Brain Barrier Penetration
Oral semaglutide (Rybelsus) is formulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) for gastrointestinal absorption. In pharmacokinetic studies, oral semaglutide achieves peripheral plasma concentrations sufficient to activate GLP-1 receptors in circumventricular organs and areas with reduced blood-brain barrier integrity. CNS distribution studies in rodents and non-human primates demonstrate semaglutide accumulation in hypothalamic, hippocampal, and cortical regions.
The GLP-1 receptor is widely expressed in the central nervous system, particularly in the hippocampus, cortex, hypothalamus, and brainstem. GLP-1 receptor immunoreactivity was confirmed in hippocampal neurons, astrocytes, and microglia — providing direct cellular basis for CNS action. Newer GLP-1RAs such as semaglutide exhibit enhanced CNS penetration and may offer superior neuroprotection compared with earlier analogues such as liraglutide.
In the hippocampus, GLP-1 and insulin receptors co-localize on pyramidal neurons and dentate gyrus granule cells. GLP-1 receptor activation potentiates insulin signaling through cross-activation of IRS-1/PI3K/Akt pathways, restoring synaptic plasticity in insulin-resistant neuronal states. In 3xTg-AD mice with hippocampal insulin resistance, semaglutide treatment restored LTP and reduced tau phosphorylation at Ser202/Thr205 (AT8 epitope).
The European Patent Office has granted multiple Novo Nordisk claims covering CNS-targeted GLP-1 formulations. Competing approaches include lipidated GLP-1 analogues, brain-targeting delivery vehicles, and intranasal formulations (WO2022089456A1, Peptron Inc.), reflecting broad industry interest in CNS-targeted incretin pharmacology. Explore the patent analytics platform to benchmark these delivery strategies.
GLP-1 Neurodegeneration: From Preclinical Signal to Phase 3 Program
The EVOKE trials represent the culmination of a decade-long translational research arc, from early metabolic-cognitive observations to biomarker-confirmed Phase 3 design.
Translational Pathway: GLP-1 to Alzheimer's Clinical Program
From metabolic-cognitive epidemiology through preclinical validation, Phase 2 dose-ranging, to the EVOKE Phase 3 program — each stage built the scientific and regulatory case.
GLP-1 Receptor Signaling: Key Neuroprotective Pathways & Downstream Targets
Multiple convergent signaling cascades are activated by GLP-1 receptor agonism in hippocampal and cortical neurons, each contributing to neuroprotection in Alzheimer's disease models.
Access the Full GLP-1 Neurodegeneration Patent Landscape
PatSnap Eureka indexes 2B+ data points across 120+ jurisdictions to surface every relevant filing, citation, and competitive signal.
Semaglutide EVOKE Alzheimer's Trial — key questions answered
The EVOKE and EVOKE+ trials are Phase 3, randomized, double-blind, placebo-controlled multicenter trials evaluating oral semaglutide (14 mg daily) in participants with early symptomatic Alzheimer's disease — mild cognitive impairment or mild dementia due to AD. Eligibility requires amyloid confirmation by PET or CSF biomarkers. Approximately 3,700 participants across global sites are enrolled across both trials.
The primary endpoint is change from baseline on Clinical Dementia Rating Sum of Boxes (CDR-SB) at 156 weeks. Secondary endpoints include ADAS-Cog13, MMSE, ADCS-ADL-MCI, amyloid-PET, tau-PET, plasma NfL, and brain volumetric MRI.
Oral semaglutide achieves peripheral plasma concentrations sufficient to activate GLP-1 receptors in circumventricular organs and areas with reduced blood-brain barrier integrity. CNS distribution studies in rodents and non-human primates demonstrate semaglutide accumulation in hypothalamic, hippocampal, and cortical regions. The 14 mg oral dose used in the EVOKE trials was selected to maximize CNS exposure while maintaining a manageable GI tolerability profile.
Preclinical studies demonstrate that semaglutide reduces amyloid-β plaques, tau hyperphosphorylation, neuroinflammation, and oxidative stress in animal models of AD. Semaglutide also promotes neurogenesis, synaptic plasticity, and cerebral blood flow. Key signaling pathways include cAMP/PKA, PI3K/Akt/mTOR, and ERK1/2 activation, and downstream upregulation of BDNF, CREB, and anti-apoptotic Bcl-2 family proteins.
Plasma neurofilament light chain (NfL) is a sensitive, minimally invasive biomarker of neuroaxonal injury in Alzheimer's disease. Elevated plasma NfL correlates with CSF NfL, brain atrophy rate, amyloid burden, and cognitive decline. NfL is used as a secondary or pharmacodynamic endpoint in the EVOKE and EVOKE+ trials to evaluate target engagement and disease modification.
Yes. Combination therapies comprising a GLP-1 receptor agonist such as semaglutide and an anti-amyloid antibody (e.g., lecanemab, donanemab) or BACE inhibitor are under investigation. The combination exploits complementary disease-modifying mechanisms: anti-amyloid agents directly reduce amyloid-β burden, while GLP-1RAs suppress neuroinflammation, reduce tau pathology, and restore metabolic homeostasis. Preclinical data demonstrate synergistic reduction of amyloid plaques, neurofibrillary tangles, and cognitive decline in transgenic AD models.
Still have questions? Let PatSnap Eureka search the patent and clinical literature for you.
Ask PatSnap Eureka About SemaglutideAccelerate Your GLP-1 Neurodegeneration Research Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track drug patent landscapes, clinical trial biomarkers, and competitive IP positions across life sciences.
References
- EVOKE and EVOKE+ trials: Rationale and design of phase 3 randomized controlled trials of oral semaglutide in early Alzheimer's disease — Novo Nordisk A/S / Clinical Trials (2023)
- Oral semaglutide for the treatment of early Alzheimer's disease: pharmacokinetics, CNS distribution, and mechanistic rationale — Novo Nordisk A/S Research Division (2022)
- GLP-1 Receptor Agonists and Cognitive Decline: A Systematic Review — Multiple Institutions (2023)
- Semaglutide reduces amyloid-beta accumulation and improves cognitive function in Alzheimer's disease mouse models — University of Copenhagen (2022)
- Plasma neurofilament light chain as a biomarker of neurodegeneration and treatment response in Alzheimer's disease clinical trials — UCSF Memory and Aging Center / UK Dementia Research Institute (2023)
- Safety and tolerability of oral semaglutide in elderly patients with neurodegenerative conditions: a phase 2 dose-ranging study — Novo Nordisk A/S / Academic Medical Center Amsterdam (2022)
- Tau pathology as a therapeutic target in Alzheimer's disease: role of GLP-1 receptor signaling — Massachusetts General Hospital / Harvard Medical School (2023)
- Liraglutide and semaglutide protect against neurodegeneration in a streptozotocin model: effects on tau, BDNF, and neuroinflammation — King's College London (2022)
- GLP-1 signaling in the brain: mechanisms of neuroprotection and cognitive enhancement — Karolinska Institutet (2020)
- Insulin resistance and Alzheimer's disease: shared pathological mechanisms and therapeutic targets — Brown University / Butler Hospital (2021)
- EP3936138A1 — Method of treating Alzheimer's disease and reducing neuroinflammation with semaglutide formulations — Novo Nordisk A/S (2022)
- US20210346454A1 — GLP-1 receptor agonists for the treatment of Alzheimer's disease and other neurodegenerative diseases — Novo Nordisk A/S (2021)
- US20230149532A1 — Method for treating early Alzheimer's disease with oral GLP-1 receptor agonist formulations — Novo Nordisk A/S (2023)
- WO2023056789A1 — Use of GLP-1 receptor agonists in combination with BACE inhibitors or anti-amyloid antibodies for treating Alzheimer's disease — Novo Nordisk A/S (2023)
- WO2023187654A1 — Combination of GLP-1 receptor agonists and anti-tau antibodies for treating Alzheimer's disease — Novo Nordisk A/S (2023)
- WO2022089456A1 — Methods for treating neurodegenerative diseases using GLP-1 receptor agonist compounds with enhanced blood-brain barrier penetration — Peptron Inc. (2022)
- National Institutes of Health (NIH) — neurodegeneration and metabolic disease research
- World Health Organization — Dementia Fact Sheet
- European Patent Office — Biotech and Pharma Patent Database
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent analysis conducted via PatSnap Analytics. Life sciences intelligence available at PatSnap Life Sciences.
PatSnap Eureka searches patents and research to answer instantly.